Matt Kaeberlein, Professor of Laboratory Medicine and Pathology at the University of Washington and director of the Healthy Aging and Longevity (HALo) Research Institute highlights the start of expanded rapamycin clinical trial for dog longevity. In this interview by Longevity Technology, Dr. Kaeberlein briefly covers his work on an initiative called The Dog Aging Project, which aims to demonstrate that companion dogs can provide a compelling model for aging and age-related disease in humans.
HALO Director Matt Kaeberlein highlights the start of expanded rapamycin clinical trials for dog longevity in interview by Longevity Technology
